Tuesday, December 17, 2024 at 2-3pm ET                       
Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Addressing gaps in patient care for adults with hypoparathyroidism with reliable treatment beyond conventional therapy.

Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH). PTH is the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidneys and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for approximately 75% of cases, while other etiologies include autoimmune and idiopathic causes.

There is a lack of treatment options for hypoparathyroidism in adults. Conventional therapy consists of oral calcium and active vitamin D, and aims to alleviate hypocalcemia but does not address insufficient parathyroid hormone (PTH). This can lead to a wide range of both short- and long-term complications.

Learning Objectives

• Understand the treatment landscape and limitations of conventional therapy for hypoparathyroidism as it relates to clinical/comorbid manifestations.
• Understand the need for additional therapies for adult patients with inadequately controlled hypoparathyroidism.
• Learn about a new therapy for treating hypoparathyroidism in adults when inadequately controlled on conventional therapy.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.